An open-label, 28-day multiple dose pilot study to evaluate the effects on lung oxidative stress, safety and pharmacokinetics of TA-270 in patients with chronic obstructive pulmonary disease (COPD).

Trial Profile

An open-label, 28-day multiple dose pilot study to evaluate the effects on lung oxidative stress, safety and pharmacokinetics of TA-270 in patients with chronic obstructive pulmonary disease (COPD).

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs TA 270 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top